Characterization of Lung Cancer Mechanosensation
ISEF · 2022 Cellular and Molecular Biology
Overview
This study is a proof-of-concept to validate if CRISPR a/i (activation/interference) system can modulate LMNA gene expression in lung cancer cells. To establish the CRISPRa/i system, I used a 2nd generation lentiviral transduction system as an effective delivery method of stably integrating desired plasmids into the host cell genome for efficient and long-term expression. The delivery process is separated into two stages: lentiviral particle production by transfecting HEK293T cells and transduction of the lentiviral particles into target A549 cells. Three plasmids {packaging plasmid, envelope plasmid, transfer plasmid} were transfected into HEK293T cells to utilize the host cell to produce lentiviruses. Following an optimized lentiviral production protocol, 3 lentiviruses for 3 different transfer plasmids of interest {Plasmid #1 VP64-GFP, Plasmid #2 dCas9-10XGCN4-BFP, Plasmid #3 dCas9-KRAB-BFP} were produced and transduced into A549 cells. Then, I used fluorescent cell sorting to select for GFP/BFP expressing cells and create A549 CRISPRa and CRISPRi cell lines. After transducing both cell lines with another lentivirus containing the gRNA for LMNA gene, I performed Western Blots to measure Lamin A/C protein level to determine if LMNA expression was modulated. I observed successful over/under expression of Lamin A/C comparative to the controlled expression of B-actin. This evidence verifies the CRISPRa/i system can modulate the expression of any targeted gene in A549 cells. Since this is a continuation project, next year, I plan to utilize the CRISPRa/i system to modulate the expression levels of specific EMT markers in A549 mechanosensitive cells to find the factors that drive mechanosensation.
Competition history
- ISEF 2022
Resources
Related projects
ISEF · 2023
Modulation of EMT Gene Expression Using CRISPRa/i to Investigate Lung Cancer Mechanosensation
ISEF · 2024
Modulating Integrin Expression in Pancreatic Tumor Cells
JSHS · 2022
The Effects of a Novel CRISPR-Cas9 System in Human Cancer Cells
ISEF · 2016
Editing of ciz1 Gene Responsible for Small Cell Lung Cancer Growth using CRISPR CAS Technology
JSHS · 2020
Development of a Novel Biomarker and Stage-Classifier Panel for Treatment and Rapid Identification of Lung Cancer by Blood Tests Utilizing Next-Generation Sequencing, Computational, and In-Vitro Analyses
ISEF · 2023
Cancer and CRISPR: A Story of Two Assays
ISEF · 2015
Identification and Characterization of a Rare Subpopulation with Cancer Stem Cell Properties in Lung Cancer
ISEF · 2021
Customized Cancer Cell Weapons: Using CRISPR dCas9 Genetic Engineering to modify MCF7 Human Breast Cancer Cells into Double Agent Treatment Vectors, Year III
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: Regeneron International Science and Engineering Fair